Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential?
TheFly reported on June 25 that Truist Securities initiated coverage of JANX with a Buy recommendation and a $26 price target, revised lower from $80.









